Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of
hematologic malignancies, offering remarkable remission rates in otherwise refractory …

Chimeric antigen receptor (CAR) T-cell therapy has achieved notable success in treating
hematological cancers but faces significant challenges in solid-tumor treatment and overall …

Background The first-in-class approved BCMA CAR-T therapy was idecabtagene vicleucel
(ide-cel), approved in March 2021, for RRMM patients who progressed after 4 or more lines …

Simple Summary Hepatocellular carcinoma (HCC) is the most common form of liver cancer
in adults. For patients with early HCC, surgery, local destructive therapies, chemotherapy …

Simple Summary Adoptive immunotherapy has emerged as an effective alternative of
mounting impact to the current standard of care in cancer, viral infections, and recently …

Simple Summary Precision oncology is at the forefront of personalized cancer care, utilizing
tumor-agnostic therapies that target specific biomarkers, such as tumor mutational burden …

The manufacturing of autologous chimaeric antigen receptor (CAR) T cells largely relies
either on fed-batch and manual processes that often lack environmental monitoring and …

Systemic autoimmune diseases (SAIDs), such as systemic lupus erythematosus (SLE),
systemic sclerosis (SSc) and rheumatoid arthritis (RA), are fully related to the unregulated …

While the advent of CAR-T therapies has heralded a new era of efficacious therapies in
relapsed/refractory Multiple Myeloma, access continues to be a major limiting factor due to …

The increasing demand for biosimilar monoclonal antibodies (mAbs) has prompted the
development of stable high-producing cell lines while simultaneously decreasing the time …